<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322981</url>
  </required_header>
  <id_info>
    <org_study_id>17-5921</org_study_id>
    <nct_id>NCT04322981</nct_id>
  </id_info>
  <brief_title>Pharmacist-led Hepatitis C Management</brief_title>
  <acronym>PHARM-C</acronym>
  <official_title>Pharmacist-led Hepatitis C Diagnosis and Rapid Management - in Community</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis C virus (HCV) continues to disproportionately affect vulnerable and marginalized
      persons in Canada. During the interferon treatment era, certain circumstances precluded
      individuals from receiving treatment, most notably mental health concerns or active substance
      use. In addition to the tolerability and efficacy of all-oral direct acting antivirals
      (DAAs), novel diagnostic strategies have also increased engagement in the care cascade.
      Point-of care and/or dried blood spot antibody as well as RNA testing allow for diagnosis
      without the need for phlebotomy, a major barrier for those with a history of past or current
      injection drug use. Despite these advances in diagnostic streamlining and increased cure
      rates, engagement post-diagnosis continues to be a major gap. Although the exact mechanism of
      HCV acquisition may not be clear - people who inject drugs, persons who are street-involved
      or low-income, or persons who are difficult-to-reach for other reasons, often experience both
      structural and geographic challenges to obtaining care. Community pharmacists may be the
      first point of contact for higher risk populations and may avoid testing and/or treatment for
      fear of judgement or poor treatment in hospital/specialist settings. While studies have
      demonstrated the feasibility of treating people receiving opioid against therapy (OAT), it
      remains unclear whether Canadian pharmacists can safely and effectively screen, and/or
      confirm HCV, work-up patients for HCV treatment, and prescribe with minimal oversight. If
      this model proves successful, it may have global utility especially in areas of the world
      where pharmacists are the initial point of contact for healthcare issues. The aim of this
      study is to determine whether being tested and linked care and treatment will be more
      effective in a community pharmacy than a referral to a tertiary care hospital for management
      of HCV among people on stable OAT, or other populations who experience barriers to care but
      use community pharmacy services.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Screening, evaluation and treatment at an outpatient pharmacy compared to referral to hepatology clinics</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intention to treat by Completion Rates</measure>
    <time_frame>24 months</time_frame>
    <description>Intention to treat direct acting antiviral (DAA) completion rates in non-cirrhotic or compensated cirrhotic patients treated with DAAs in pharmacist-led programs in community pharmacies, compared to treatment completion rates with referral and treatment in tertiary care hepatology (Toronto Centre for Liver Disease).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained Virologic Response by Intention-to-Treat</measure>
    <time_frame>24 months</time_frame>
    <description>Compare Sustained Virologic Response rates by Intention to treat in both sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Virologic Response by modified Intention-to-Treat</measure>
    <time_frame>24 months</time_frame>
    <description>Compare the rates of Sustained Virologic Response by modified Intention to treat (including all participants who take at least one dose of medication)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Virologic Response by Per Protocol analysis</measure>
    <time_frame>24 months</time_frame>
    <description>Compare the rates of Sustained Virologic Response by per protocol analysis including all individuals who complete treatment in both groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatitis C Community seroprevalence in downtown Toronto</measure>
    <time_frame>18 months</time_frame>
    <description>Determine the seroprevalence of HCV among individuals tested in downtown Toronto.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Community Pharmacist Fibrosis Identification</measure>
    <time_frame>18 months</time_frame>
    <description>Comparison of pharmacist-assessed fibrosis stage vs fibrosis stage assessed by hepatologist (gold standard)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Community Pharmacist Decompensation Identification</measure>
    <time_frame>18 months</time_frame>
    <description>Comparison of pharmacist-assessed hepatic decompensation score vs hepatic decompensation assessed by hepatologist (gold standard)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Mean Time-to-Treatment</measure>
    <time_frame>18 months</time_frame>
    <description>Determine the minimum mean time-to-treatment initiation in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Community Appointment Adherence</measure>
    <time_frame>24 months</time_frame>
    <description>Assess appointment adherence in both arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Adherence</measure>
    <time_frame>18 months</time_frame>
    <description>Assess self-reported medication adherence at both sites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life and Substance Use</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluate quality of life for patients with chronic liver disease (CLDQ-HCV) before and after treatment (endpoint and SV12) at both sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substance Use</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluate the Maudsley Addiction Profile (MAP) before and after treatment (endpoint and SV12) at both sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Understanding and Satisfaction</measure>
    <time_frame>24 months</time_frame>
    <description>Compare patient understanding and satisfaction with HCV treatment with the Hepatitis Patient Satisfaction Questionnaire (HPSQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reinfection</measure>
    <time_frame>24 months</time_frame>
    <description>Assess rates of reinfection in patients who achieve Sustained Virologic Response, at 48 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient empowerment</measure>
    <time_frame>24 months</time_frame>
    <description>Compare measure of patient empowerment by treatment-arm using the Health Care Empowerment (HCE) survey</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Hepatitis C Virus Infection</condition>
  <arm_group>
    <arm_group_label>Community Pharmacist-Led</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in Arm 1 will receive care and treatment at their home pharmacy and be evaluated and treated by a community pharmacist under medical directives and with study oversight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Academic hepatology</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in Arm 2 will be evaluated and treated by hepatologists at the Toronto Centre for Liver Disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Pharmacist-Led care</intervention_name>
    <description>Rapid testing in a community pharmacy, with rapid linkage to care and treatment that is pharmacist-led</description>
    <arm_group_label>Community Pharmacist-Led</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard of Care (Hepatology)</intervention_name>
    <description>Rapid testing in a community pharmacy, with standard of care referral to academic hepatology</description>
    <arm_group_label>Academic hepatology</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HCV infection

          2. HCV RNA &gt; 1,000 IU/mL

          3. Aged 18 to 80

          4. Willingness and capacity to provide informed consent

        Exclusion Criteria:

          1. Presence of or history of decompensated cirrhosis. This will be defined as evidence of
             clinical decompensation (history of either ascites, variceal hemorrhage, or hepatic
             encephalopathy/confusion), and Child-Pugh-Turcotte and Model for Endstage Liver
             Disease (MELD) score will also be used to assess this using laboratory investigations
             and clinical findings.

          2. Platelets &lt; 75,000/mm3, total albumin &lt;35 g/L, total bilirubin (total and direct)
             &gt;34.2 Î¼mol/L, International Normalized Ratio (INR) &gt;1.5

          3. History of current or past hepatocellular carcinoma

          4. Hepatitis B virus (HBV) co-infection as indicated by positive testing for hepatitis B
             surface antigen (HBsAg +ve)or untreated HIV co-infection

          5. Prior HCV antiviral therapy with direct-acting antivirals with or without
             peginterferon/ribavirin

          6. Chronic liver disease other than mild non-alcoholic or alcoholic fatty liver disease
             from a cause other than HCV

          7. Significant co-morbid illness that precludes inclusion in the opinion of the
             investigator

          8. Life expectancy of less than 1 year. If clarity is required, the provider who
             delivered the diagnosis will be contacted.

          9. Pregnancy/breast-feeding/inability to use contraception

         10. Use of concomitant contraindicated drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mia Biondi, PhD, NP-PHC</last_name>
    <phone>6476286471</phone>
    <email>mia.biondi@mail.mcgill.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jordan Feld, MD, MPH</last_name>
    <phone>4163404584</phone>
    <email>jordan.feld@uhn.ca</email>
  </overall_contact_backup>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Point-of-care testing</keyword>
  <keyword>Rapid access to treatment</keyword>
  <keyword>Pharmacist-led</keyword>
  <keyword>Service co-localization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

